| First Author | Apolinário LM | Year | 2015 |
| Journal | Anat Rec (Hoboken) | Volume | 298 |
| Issue | 9 | Pages | 1589-96 |
| PubMed ID | 26011009 | Mgi Jnum | J:224775 |
| Mgi Id | MGI:5689058 | Doi | 10.1002/ar.23177 |
| Citation | Apolinario LM, et al. (2015) Long-Term Therapy With Omega-3 Ameliorates Myonecrosis and Benefits Skeletal Muscle Regeneration in Mdx Mice. Anat Rec (Hoboken) 298(9):1589-96 |
| abstractText | In Duchenne muscle dystrophy (DMD) and in the mdx mouse model of DMD, a lack of dystrophin leads to myonecrosis and cardiorespiratory failure. Several lines of evidence suggest a detrimental role of the inflammatory process in the dystrophic process. Previously, we demonstrated that short-term therapy with eicosapentaenoic acid (EPA), at early stages of disease, ameliorated dystrophy progression in the mdx mouse. In the present study, we evaluated the effects of a long-term therapy with omega-3 later in dystrophy progression. Three-month-old mdx mice received omega-3 (300 mg/kg) or vehicle by gavage for 5 months. The quadriceps and diaphragm muscles were removed and processed for histopathology and Western blot. Long-term therapy with omega-3 increased the regulatory protein MyoD and muscle regeneration and reduced markers of inflammation (TNF-alpha and NF-kB) in both muscles studied. The present study supports the long-term use of omega-3 at later stages of dystrophy as a promising option to be investigated in DMD clinical trials. Anat Rec, 298:1589-1596, 2015. (c) 2015 Wiley Periodicals, Inc. |
